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A clinical trial has been reported which achieves the cure of haemophilia B , but in some restricted 
patients.
Gene therapy will become the definitive treatment to cure haemophilia B
Introduction
If it is possible, it will be used liver as a target tissue
Haemophilia B is a monogenic hereditary X-linked bleeding disorder that results from a defect in the gene encoding coagulation factor IX which frequency in males
of 1/25,000. People with severe haemophilia have <1% of the normal clotting factor in their blood and levels considered therapeutic are slightly above the 1%
threshold and can convert severe haemophilia into a moderate form.
Current treatment involves frequent intravenous injection of clotting factor concentrates two or three times a week. This treatment is prophylactic rather than
curative, moreover, in some cases there is a complication with the formation of antibodies ‘inhibitors’ which block the recombinant protein.
Gene therapy would be a very attractive treatment to cure the disease allowing endogenous production of FIX. For these reasons, researchers are developing new
and improved cassettes and vectors designs, doses optimization and they are finding new alternatives with non-viral vectors.
The objective of this study is to investigate the approaches which allow more efficient vector design and cassettes to optimize haemophilia gene therapy.
The aim to improve the
cassette design is to achieve a
long-term expression and de-
crease the immune response. It
could be achieved by specific-
promoter, hyperfunctional muta-
tion, codon usage optimization,
silent sequences among others
Tolerance 
Induction
Alternative 
Serotypes
Alternatives 
Strategies
The patients could develop
capsid-specific T-cell response
and/or inhibitors antibodies
against the transgene. In order
to avoid these, it can
immunosuppress the patients
and/or introduce tregitopes in
the cassette.
The safest and most efficient
serotypes are AAV2/7, AAV2/8
and AAV2/9 because of they
do not develop inhibitors and it
maintain transgene expression
Cassette 
Design
Tranposon-transposase System: it allows
the transgene FIX insertion in the murine
genome with a liver-specific promoter and
results in a stable and long-term
expression
Zinc Finger Nucleases: it induces double-
strand breaks to insert the cassette in the
murine genome and results in a long-term
expression
Problems Solutions
rFIX
Current Treatment New Therapy
AAV
Liver Muscle
Non-invasive administration Non-invasive administration
Normally produces and secretes  FIX into the 
blood system
Capacity of produce FIX and secretes it into the 
bloodstream
Long-term and therapeutic level expression of the 
transgene
Alternative target in cases of liver disease
Immune Tolerance can be induced to the transgene
T-cell cytotoxic response Inhibitor antibodies
Liver diseases Long-term expression but in sub-therapeutic levels
Nathwani, A.C. et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365, 2357-65 (2011).
Mingozzi, F. & High, K.A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12,
341-55 (2011).
Finn, J.D. et al. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle
gene therapy. Blood 120, 4521-3 (2012).
Wang, L. et al. Muscle-directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors. J Thromb
Haemost 9, 2009-19 (2011).
Approaches
Target tissues Future Directions
References
